The Korean Journal of Hematology最新文献

{"title":"Asymptomatic pneumatosis intestinalis following chemotherapy for B lymphoblastic leukemia with recurrent genetic abnormalities in an adolescent patient.","authors":"Dae-Kyu Shin,&nbsp;Jisu Oh,&nbsp;Harry Yoon,&nbsp;Jo Eun Kim,&nbsp;So Young Chong,&nbsp;Doyeun Oh","doi":"10.5045/kjh.2012.47.1.74","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.74","url":null,"abstract":"<p><p>Pneumatosis intestinalis (PI) is a rare condition characterized by multiple pneumocysts in the submucosa or subserosa of the bowel. Here, we report a rare case of asymptomatic PI after chemotherapy induction in an 18-yr-old man with B lymphoblastic leukemia with recurrent genetic abnormalities. The patient was treated conservatively and recovered without complications. The possibility of PI should be considered as a complication during or after chemotherapy for hematologic malignancies. Conservative treatment should be considered unless there are complications, including peritonitis, bowel perforation, and severe sepsis.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"74-6"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.74","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008.","authors":"Hyeon Jin Park,&nbsp;Eun-Hye Park,&nbsp;Kyu-Won Jung,&nbsp;Hyun-Joo Kong,&nbsp;Young-Joo Won,&nbsp;Joo Young Lee,&nbsp;Jong Hyung Yoon,&nbsp;Byung-Kiu Park,&nbsp;Hyewon Lee,&nbsp;Hyeon-Seok Eom,&nbsp;Sohee Park","doi":"10.5045/kjh.2012.47.1.28","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.28","url":null,"abstract":"<p><strong>Background: </strong>The nationwide statistical analysis of hematologic malignancies in Korea has not been reported yet.</p><p><strong>Methods: </strong>The Korea Central Cancer Registry and the Korean Society of Hematology jointly investigated domestic incidence rates and prevalence of hematologic malignancies occurred between 1999 and 2008, and analyzed survival rates of patients who were diagnosed between 1993 and 2008. Data of hematologic malignancies from 1993 to 2008 were obtained from the Korean National Cancer Incidence Data base. The crude incidence rates, age-specific incidence rates, age-standardized incidence rates, annual percentage change of incidence, and prevalence from 1999-2008 were calculated. Survival rates for patients diagnosed in 1993-2008 were estimated.</p><p><strong>Results: </strong>In 2008, a total of 8,006 cases of hematologic malignancies were occurred, which comprised 4.5% of all malignancies. In all genders, non-Hodgkin lymphoma, myeloid leukemia, and multiple myeloma were most frequent diseases. In terms of age, ages between 60 and 69 were most prevalent. From 1999 to 2008, the age-standardized incidence rates increased from 10.2 to 13.7, and the annual percentage change was 3.9%. The 5-year survival rate increased from 38.2% during 1993-1995 to 55.2% during 2004-2008. As of January 2009, number of patients with 10-year prevalence was 33,130, and with 5- to 10-year prevalence was 10,515.</p><p><strong>Conclusion: </strong>This is the first nationwide statistical report of hematologic malignancies in Korea. It could be used as the basic information to help investigate epidemiologic characteristics, evaluate progress during the past years, and establish future strategies for hematologic malignancies. Periodic statistical analysis of hematologic malignancies in Korea should be continued.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"28-38"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.28","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of anti-PF4/heparin antibody test for intensive care unit patients with thrombocytopenia.","authors":"Sang Hyuk Park,&nbsp;Seongsoo Jang,&nbsp;Hyoeun Shim,&nbsp;Geum-Borae Park,&nbsp;Chan-Jeoung Park,&nbsp;Hyun-Sook Chi,&nbsp;Sang-Bum Hong","doi":"10.5045/kjh.2012.47.1.39","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.39","url":null,"abstract":"<p><strong>Background: </strong>It is critical to differentiate heparin-induced thrombocytopenia (HIT) from disseminated intravascular coagulation (DIC) in heparinized intensive care unit (ICU) patients with thrombocytopenia because the therapeutic approach differs based on the cause. We investigated the usefulness of PF4/heparin antibody tests in these patients.</p><p><strong>Methods: </strong>A total of 127 heparinized ICU patients whose platelet counts were <150×10(9)/L or reduced by >50% after 5-10 days of heparin therapy were enrolled. PF4/heparin antibodies were measured using 2 immunoassays. We assessed the probability of HIT by using Warkentin's 4T's scoring system for antibody positive patients and compared routinely performed coagulation test results between patients with and without antibodies to evaluate the ability of these tests to discriminate between HIT and DIC.</p><p><strong>Results: </strong>Positive results were obtained for 14 (11.0%) and 11 (8.7%) patients in the 2 assays. The analysis performed using the 4T's scoring system revealed that 11 of 20 (15.7%) patients with antibodies in at least 1 assay had intermediate or greater probability of HIT. Patients without antibodies had significantly higher levels of D-dimer than those with antibodies. However, there were no intergroup differences in platelet counts, PT, aPTT, fibrinogen, DIC score, and rate of overt DIC.</p><p><strong>Conclusion: </strong>Seropositivity for PF4/heparin antibody was 8.7-11.0% in the patients with thrombocytopenia, and more than a half of them had an increased probability of HIT. Among the routine coagulation tests, only D-dimer was informative for differentiating HIT from DIC. PF4/heparin antibody test is useful to ensure appropriate treatment for thrombocytopenic heparinized ICU patients.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"39-43"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Indeterminate lupus anticoagulant\" as the third category.","authors":"Sang Hyuk Park,&nbsp;Seongsoo Jang","doi":"10.5045/kjh.2012.47.1.83","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.83","url":null,"abstract":"TO THE EDITOR: \u0000 \u0000Laboratory testing for the detection of lupus anticoagulant (LAC) is important for the diagnosis of antiphospholipid syndromes and hypercoagulable states. LACs are heterogeneous circulating autoantibodies directed against epitopes found on negatively charged phospholipids and proteins associated with the cell membrane and inhibit phospholipid-dependent coagulation tests in vitro. However, LAC is actually prothrombotic agents and cause thrombosis in vivo; therefore, accurate diagnosis is critical for risk assessment and long-term patient management with anticoagulants. \u0000 \u0000To improve the diagnostic sensitivity of LAC testing, the International Society of Thrombosis and Haemostasis (ISTH) published testing guidelines in 1995 [1], and in 2009, it updated guidelines for LAC detection, patient selection, choice of tests, calculation of cut-off value, and interpretation of results [2]. Although mixing studies are simple in principle, interpretation of their results poses a considerable challenge. The 2009 ISTH guidelines recommended using the 99th percentile of the normal values as a cut-off for determining clotting time correction. When the concentrations of LAC are low, the clotting time after mixing can erroneously return to the normal range, and the results may be interpreted as negative. This shows that low concentrations of LAC cannot be detected when the 99th percentile of the normal values is used as a cut-off. \u0000 \u0000Therefore, it is necessary to adopt a more stratified diagnostic strategy for LAC, especially for the clotting-time based test, to reduce the possibility of a false-negative result when the concentration of LAC is low. In this context, separate, third strategy should be introduced for individuals with \"indeterminate LAC\". The results can be classified as \"indeterminate LAC\" when the outcomes of both LAC screening and the confirmatory test are positive but that of the mixing test is weakly positive. By introducing \"indeterminate LAC\" as a separate category, we can focus on patients who are thought to have a low concentration of LAC. \u0000 \u0000Alkayed and Kottke-Marchant reported that indeterminate LAC results were common, and that the clinical characteristics of these individuals differed from those with negative results [3]. In our laboratory, we classify LAC test results into 3 different categories: positive, negative, and indeterminate. Our data also show that patients with \"indeterminate LAC\" have heterogeneous clinical characteristics, from absence of clinical symptoms to evident deep-vein thrombosis, pulmonary thromboembolism, or recurrent fetal loss. If indeterminate LAC results are ignored, these thrombotic diseases may remain undiagnosed. \u0000 \u0000We think that adding this third category will prove to be a good strategy both practically and clinically. We completely agree with the opinion of Alkayed and Kottke-Marchant.","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"83"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.83","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular immunotherapy using dendritic cells against multiple myeloma.","authors":"Thanh-Nhan Nguyen-Pham,&nbsp;Youn-Kyung Lee,&nbsp;Hyun-Ju Lee,&nbsp;Mi-Hyun Kim,&nbsp;Deok-Hwan Yang,&nbsp;Hyeoung-Joon Kim,&nbsp;Je-Jung Lee","doi":"10.5045/kjh.2012.47.1.17","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.17","url":null,"abstract":"<p><p>Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4(+) T cells and CD8(+) cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"17-27"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histoplasmosis on bone marrow aspirate cytological examination associated with hemophagocytosis and pancytopenia in an AIDS patient.","authors":"Harish Chandra,&nbsp;Smita Chandra,&nbsp;Anita Sharma","doi":"10.5045/kjh.2012.47.1.77","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.77","url":null,"abstract":"<p><p>A 38-year-old woman who presented with unexplained fever and pancytopenia was subjected to a bone marrow examination. Her bone marrow aspirate smear showed no obvious pathological finding except for the presence of hemophagocytosis and mild plasmacytosis. In view of hemophagocytosis, a thorough examination of the smear was conducted and revealed the presence of histoplasmosis. She was advised to undergo evaluation of her immunological status, and she tested positive for human immunodeficiency virus (HIV) infection. This case highlights that hemophagocytosis in the marrow may be an early sign of underlying disease, and that careful examination of bone marrow smears may reveal subtle infections. In addition, histoplasmosis with hemophagocytosis may be associated with pancytopenia, and hence, the HIV status of the patient should always be investigated.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"77-9"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.77","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic myeloid leukemia with extreme thrombocytosis.","authors":"So Young Kim,&nbsp;You La Jeon,&nbsp;Tae Sung Park","doi":"10.5045/kjh.2012.47.1.7","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.7","url":null,"abstract":"which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. A 51-year-old man with no specific medical history was brought to our hospital with general weakness. Complete blood smear showed marked increase in giant platelets and hypogranulated platelets (A). Bone marrow aspirate displayed normal erythropoiesis and increased granulopoiesis, and a notable finding was marked increase in the number of small megakaryocytes, namely, \" dwarf megakarytocytes. \" However, a few megakaryocytes showed hyperplastic features (B). Essential thrombocythemia (ET) was preferentially considered over other myeloproliferative neoplasms (MPNs). However, both JAK2 V617F and MPL 515 mutations were not detected. Interestingly, the Philadelphia chromosome was detected in 19 out of 20 bone-marrow metaphase cells analyzed. Subsequently, BCR/ABL1 fluorescence in situ hybridization (FISH) analysis yielded a positive result. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for BCR/ABL1 rearrangement showed the presence of the b3a2 fusion gene. Finally, the patient was diagnosed with chronic myeloid leukemia (CML) associated with extreme thrombocytosis (C). After one course of imatinib treatment, the patient's platelet count was reduced to normal levels. Although CML is easily predicted by approaches of morphologic basis, cases with extreme thrombocytosis would require molecular techniques such as chromosome, FISH and RT-PCR for a proper differential diagnosis including other disorders of MPN such as ET.","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children.","authors":"Keun Wook Bae,&nbsp;Bo Eun Kim,&nbsp;Kyung Nam Koh,&nbsp;Ho Joon Im,&nbsp;Jong Jin Seo","doi":"10.5045/kjh.2012.47.1.44","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.44","url":null,"abstract":"<p><strong>Background: </strong>Immune reconstitution (IR) after hematopoietic stem cell transplantation (HSCT) reduces transplantation-related complications such as infection and improves HSCT outcomes.</p><p><strong>Methods: </strong>We retrospectively analyzed IR of lymphocyte subpopulations in 38 pediatric patients for hematologic malignant diseases after allogeneic HSCT from April 2006 to July 2008. T-cell-, B-cell-, and natural killer (NK) cell-associated antigens were assayed in peripheral blood by flow cytometry analysis of 5 lymphocyte subsets, CD3+, CD3+/CD4+, CD4+/CD8+, CD16+/CD56+, and CD19+, before and 3 and 12 months after transplantation.</p><p><strong>Results: </strong>Reconstitutions of CD16+/CD56+ and CD3+/CD8+ lymphocytes were achieved rapidly, whereas that of CD3+/CD19+ lymphocytes occurred later. Age was not related to reconstitution of any lymphocyte subset. Total body irradiation (TBI) and anti-thymocyte globulin (ATG) administration were related to delayed reconstitution of total lymphocytes and CD3+ lymphocytes, respectively. Reconstitutions of CD3+/CD4+ lymphocytes and CD3+/CD8+ lymphocytes were significantly delayed in patients who received umbilical cord blood stem cells. In patients with chronic graft-versus-host disease (cGVHD), recovery of the total lymphocyte count and CD19+ lymphocytes at 3 months post-transplant were significantly delayed. However, acute GVHD (aGVHD) and cytomegalovirus (CMV) reactivation did not influence the IR of any lymphocyte subset. Further, delayed reconstitution of lymphocyte subsets did not correspond to inferior survival outcomes in this study.</p><p><strong>Conclusion: </strong>We observed that some lymphocyte reconstitutions after HSCT were influenced by the stem cell source and preparative regimens. However, delayed CD19+ lymphocyte reconstitution may be associated with cGVHD.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"44-52"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas.","authors":"Jeong Eun Kim,&nbsp;Dok Hyun Yoon,&nbsp;Geundoo Jang,&nbsp;Dae Ho Lee,&nbsp;Shin Kim,&nbsp;Chan-Sik Park,&nbsp;Jooryung Huh,&nbsp;Won Seog Kim,&nbsp;Jinny Park,&nbsp;Jae Hoon Lee,&nbsp;Soon Il Lee,&nbsp;Cheolwon Suh","doi":"10.5045/kjh.2012.47.1.53","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.1.53","url":null,"abstract":"<p><strong>Background: </strong>Bortezomib targets molecular dysregulation of nuclear factor-κB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of bortezomib treatment with dose-dense cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 2 weeks (CHOP-14).</p><p><strong>Methods: </strong>Untreated DLBCL patients were enrolled. A phase I dose-escalation study with 1.0, 1.3, and 1.6 mg/m(2) bortezomib administration on day 1 and 4 in addition to the CHOP-14 regimen was performed to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT). Lenograstim 5 µg/kg/d was administered on day 4-13. The bortezomib dose from the phase I study was used in the phase II study.</p><p><strong>Results: </strong>Nine and 37 patients were enrolled in the phase I and phase II studies, respectively. The analysis of the phase II results (40 patients) included data of the 3 patients in the last MTD dose cohort of the phase I trial. During the phase I trial, no DLT was observed at any bortezomib dose; therefore, the recommended dose was 1.6 mg/m(2). In phase II, the overall response rate was 95% (complete response: 80%; partial response: 15%). Nine out of the 40 patients showed grade 3 sensory neuropathy, and 22 required at least 1 dose reduction. Three patients could not complete the intended 6 cycles of treatment because of severe neuropathy.</p><p><strong>Conclusion: </strong>Bortezomib plus CHOP-14 was highly effective for the treatment of untreated DLBCL patients, but in many cases, dose or schedule modification was required to reduce neurotoxicity.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"53-9"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30554580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats.","authors":"Akanni E Olufemi, Alli O A Terry, Oloke J Kola","doi":"10.5045/kjh.2012.47.1.67","DOIUrl":"10.5045/kjh.2012.47.1.67","url":null,"abstract":"<p><strong>Background: </strong>The use of natural bioactive compounds in conventional chemotherapy is a new direction in cancer treatment that is gaining more research attention recently. Bioactive polysaccharides and polysaccharide-protein complexes from some fungi (edible mushrooms) have been identified as sources of effective and non-toxic antineoplastic agents. Selected oyster mushrooms (Pleurotus pulmonarius and P. ostreatus being local [Nigeria] and exotic strains, respectively) were cultured on a novel medium of yeast extract supplemented with an ethanolic extract of Annona senegalensis, and the antileukemic potential of their metabolites was studied.</p><p><strong>Methods: </strong>Leukemia was successfully induced in Wister rats by intravenous injection (0.2 mL) of a benzene solution every 2 days for 3 consecutive weeks. The aqueous solution of fungal metabolites (20 mg/mL) produced by submerged fermentation was orally administered (0.2 mL) before, during, and after leukemia induction. Leukemia burden was assessed by comparing the hematological parameters at baseline and after leukemia induction. The immunomodulatory potential of the metabolites was assessed by using a phagocytic assay (carbon clearance method). The ability to enhance leukopoiesis was assessed by using the total leukocyte count.</p><p><strong>Results: </strong>Leukemia induction resulted in significant anemia indices and leukocytosis (P<0.05) in the experimental rats. Both metabolites equally enhanced leukopoiesis and demonstrated phagocytic actions; P. ostreatus activity was significantly higher than that of P. pulmonarius (P<0.05).</p><p><strong>Conclusion: </strong>The metabolites exhibited profound antileukemic potential by suppressing leukemia and demonstrating immunotherapeutic activities on animals after oral administration in various experimental groups.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"67-73"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/1e/kjh-47-67.PMC3317474.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}